

Review of: "Italian Position Paper (SIPMO-SICMF) on Medication-Related Osteonecrosis of the Jaw (MRONJ)"

Florelle Gindraux¹

¹ Centre Hospitalier Régional et Universitaire de Besançon

Potential competing interests: No potential competing interests to declare.

The paper covers fully the question of Medication- Related Osteonecrosis of the Jaw.

However, an updated definition of Ruggiero, S.L., et al., American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg, 2022 is crucial:

1. Current or previous treatment with antiresorptive therapy alone or in combination with immune modulators or antiangiogenic medications.
2. Exposed bone or bone that can be probed through an intraoral or extraoral fistula(e) in the maxillofacial region that has persisted for more than 8 weeks.
3. No history of radiation therapy to the jaws or metastatic disease to the jaws.

More over, it is really essential to implement some missing data highlighted by Gaudet, C.; Odet, S.; Meyer, C.; Chatelain, B.; Weber, E.; Parmentier, A.-L.; Derruau, S.;

Laurence, S.; Mauprivez, C.; Brenet, E.; et al. Reporting Criteria for

Clinical Trials on Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review and Recommendations. Cells 2022, 11, 4097. <https://doi.org/10.3390/cells11244097>.